Telehealth companies
Coverage of Telehealth companies in the Nexus archive.
- Doctors and the FDA are raising alarms over compounded weight loss drugs
The FDA issued 25 warning letters to telehealth companies over misleading claims about compounded versions of drugs like Ozempic. Doctors and the FDA are raising concerns about these compounded weight loss drugs.
- The Peptide Gold Rush Is Coming
BPC-157, a peptide rumored to treat various conditions, has gained popularity through influencers and Robert F. Kennedy Jr. An FDA advisory committee recommended allowing compounding pharmacies to produce it despite limited safety data. Telehealth companies may soon offer it if the FDA approves the recommendation.
- Inside the unconventional FDA panel that could reshape the peptide industry
An FDA advisory panel led by Robert F. Kennedy Jr. is reviewing seven banned therapeutic peptides, including BPC-157, TB-500, and epitalon, amid concerns over safety and efficacy. The two-day meeting (July 23-24) includes panelists with ties to peptide research, sales, or prescription, marking an unconventional approach to regulatory evaluation.
- Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies provide lifestyle support to help individuals taking obesity drugs achieve weight loss success. Employers, however, are pressuring these telehealth providers to restrict spending on the drugs.
- Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies provide lifestyle support to maximize weight loss success for individuals taking obesity drugs. Employers, however, are urging these providers to restrict spending on such medications.